Mirum Pharmaceuticals To Showcase LIVMARLI Data From Its ALGS And PFIC Programs At The NASPGHAN Annual Meeting
Mirum Pharmaceuticals To Showcase LIVMARLI Data From Its ALGS And PFIC Programs At The NASPGHAN Annual Meeting
mirum pharmaceuticals將在NASPGHAN年會上展示其ALGS和PFIC項目的LIVMARLI數據
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting taking place November 6-9, 2024, in Hollywood, Florida. Data highlighting clinical benefit and real-world evidence for patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC), treated with LIVMARLI (maralixibat) oral solution, will be presented during the meeting.
Mirum Pharmaceuticals公司（納斯達克股票代碼：MIRM）今天宣佈將參加2024年11月6日至9日在佛羅里達好萊塢舉行的北美兒科腸胃肝營養學會（NASPGHAN）年會。屆時將介紹使用LIVMARLI（maralixibat）口服溶液治療ALGS（阿拉吉爾綜合徵）和PFIC（進行性家族性肝內膽汁淤積症）患者的臨床益處和現實證據的數據。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間